Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

The president has said the law is unfair to U.S. businesses. But lawyers say weakening it could end up costing corporate ...

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

He was succeeded by Ian Read and later Albert Bourla. Perhaps unsurprisingly for the biggest company in one of the biggest industries in the world, Pfizer has also been proficient in exerting its ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...